Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$72.0 million.

  • NewAmsterdam Pharma Co N.V's Net Income towards Common Stockholders fell 332.54% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 11.15%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.54% down from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Net Income towards Common Stockholders of -$72.0 million as of Q3 2025, which was down 314.68% from -$17.4 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Net Income towards Common Stockholders high stood at -$16.6 million for Q3 2024, and its period low was -$93.8 million during Q1 2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Net Income towards Common Stockholders value was -$42.0 million (recorded in 2023), while the average stood at -$49.8 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 64.68% in 2024, then plummeted by 332.54% in 2025.
  • NewAmsterdam Pharma Co N.V's Net Income towards Common Stockholders (Quarterly) stood at -$49.5 million in 2023, then crashed by 86.34% to -$92.2 million in 2024, then crashed by 332.54% to -$72.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$72.0 million for Q3 2025, versus -$17.4 million for Q2 2025 and -$39.5 million for Q1 2025.